Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
DRUG

SAR445088 (IV)

Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

DRUG

SAR445088 (SC)

Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Trial Locations (32)

10032

Columbia University Site Number : 8400005, New York

11000

Investigational Site Number : 6880001, Belgrade

Investigational Site Number : 6880002, Belgrade

13385

Investigational Site Number : 2500001, Marseille

16132

Investigational Site Number : 3800003, Genova

18000

Investigational Site Number : 6880003, Niš

20089

Investigational Site Number : 3800005, Rozzano

20132

Investigational Site Number : 3800001, Milan

37075

Investigational Site Number : 2760002, Göttingen

40225

Investigational Site Number : 2760001, Düsseldorf

45147

Investigational Site Number : 2760003, Essen

46026

Investigational Site Number : 7240003, Valencia

55414

University of Minnesota Site Number : 8400006, Minneapolis

66205

The University of Kansas Clinical Research Center Site Number : 8400003, Fairway

72076

Investigational Site Number : 2760004, Tübingen

90033

University of Southern California Site Number : 8400004, Los Angeles

92380

Investigational Site Number : 2500004, Garches

92868

University of California Irvine Site Number : 8400002, Orange

94275

Investigational Site Number : 2500005, Le Kremlin-Bicêtre

200040

Investigational Site Number : 1560001, Shanghai

350001

Investigational Site Number : 1560002, Fuzhou

430030

Investigational Site Number : 1560004, Wuhan

J8Y 1W2

Investigational Site Number : 1240001, Gatineau

G1J 1Z4

Investigational Site Number : 1240002, Québec

Unknown

Investigational Site Number : 2500003, Bordeaux

06002

Investigational Site Number : 2500002, Nice

00168

Investigational Site Number : 3800002, Rome

1105AZ

Investigational Site Number : 5280001, Amsterdam

3584 CX

Investigational Site Number : 5280002, Utrecht

20-954

Investigational Site Number : 6160001, Lublin

08035

Investigational Site Number : 7240002, Barcelona

08041

Investigational Site Number : 7240001, Barcelona

All Listed Sponsors
lead

Bioverativ, a Sanofi company

INDUSTRY